A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.14726

Related search